Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction.

Bageghni SA, Hemmings KE, Yuldasheva NY, Maqbool A, Gamboa-Esteves FO, Humphreys NE, Simonsen Jackson M, Denton CP, Francis S, Porter KE, Ainscough JFX, Pinteaux E, Drinkhill MJ, Turner NA.

JCI Insight. 2019 Aug 8;5. pii: 125074. doi: 10.1172/jci.insight.125074.

2.

Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.

Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, Matucci-Cerinic M, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirják L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli A, Krummel-Lorenz B, Rednic S, Allanore Y, Müeller-Ladner U.

Ann Rheum Dis. 2019 Aug 7. pii: annrheumdis-2019-215486. doi: 10.1136/annrheumdis-2019-215486. [Epub ahead of print]

PMID:
31391176
3.

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis - Results of a Phase 2 Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial.

Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox D, Furst DE.

Arthritis Rheumatol. 2019 Jul 24. doi: 10.1002/art.41055. [Epub ahead of print]

PMID:
31342624
4.

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.

Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V.

Curr Med Res Opin. 2019 Aug 2:1-10. doi: 10.1080/03007995.2019.1647040. [Epub ahead of print]

PMID:
31328965
5.

Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis.

Almadori A, Griffin M, Ryan CM, Hunt DF, Hansen E, Kumar R, Abraham DJ, Denton CP, Butler PEM.

PLoS One. 2019 Jul 17;14(7):e0218068. doi: 10.1371/journal.pone.0218068. eCollection 2019.

6.

Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosis.

Sha M, Griffin M, Denton CP, Butler PE.

Microvasc Res. 2019 Jul 1;126:103890. doi: 10.1016/j.mvr.2019.103890. [Epub ahead of print]

PMID:
31271765
7.

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Sep;78(9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. Epub 2019 Jun 21.

8.

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

Wells A, Devaraj A, Renzoni EA, Denton CP.

Semin Respir Crit Care Med. 2019 Apr;40(2):184-193. doi: 10.1055/s-0039-1684020. Epub 2019 May 28.

PMID:
31137059
9.

Pulmonary Complications of Connective Tissue Disease.

Wells A, Denton CP.

Semin Respir Crit Care Med. 2019 Apr;40(2):145-146. doi: 10.1055/s-0039-1688716. Epub 2019 May 28. No abstract available.

PMID:
31137055
10.

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.

Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirják L, Denton CP, Distler O, Allanore Y, Müller-Ladner U, Moggi-Pignone A, Matucci-Cerinic M, Del Galdo F; EUSTAR co-workers.

Clin Rheumatol. 2019 May 20. doi: 10.1007/s10067-019-04564-8. [Epub ahead of print]

PMID:
31111363
11.

Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis.

Denton CP, Murray C.

Arthritis Res Ther. 2019 Mar 27;21(1):81. doi: 10.1186/s13075-019-1872-4.

12.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

13.

Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis.

Campochiaro C, Lytton S, Nihtyanova S, Fuchs D, Ong VH, Denton CP.

Clin Immunol. 2019 Feb;199:18-24. doi: 10.1016/j.clim.2018.12.009. Epub 2019 Feb 14.

PMID:
30771500
14.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.

Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirják L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, Matucci-Cerinic M; EUSTAR co-workers.

Arthritis Res Ther. 2019 Jan 24;21(1):35. doi: 10.1186/s13075-019-1822-1.

15.

Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure.

Nagel C, Marra AM, Benjamin N, Blank N, Cittadini A, Coghlan G, Distler O, Denton CP, Egenlauf B, Fiehn C, Fischer C, Harutyunova S, Hoeper MM, Lorenz HM, Xanthouli P, Bossone E, Grünig E.

Arthritis Rheumatol. 2019 May;71(5):805-816. doi: 10.1002/art.40814. Epub 2019 Apr 10.

PMID:
30615302
16.

Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency.

Campochiaro C, Atay S, Clark KEN, Ong V, Denton CP.

BMJ Case Rep. 2019 Jan 3;12(1). pii: e223180. doi: 10.1136/bcr-2017-223180.

PMID:
30610030
17.

A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility.

González-Serna D, Carmona EG, Ortego-Centeno N, Simeón CP, Solans R, Hernández-Rodríguez J, Tolosa C, Castañeda S, Narváez J, Martinez-Valle F; European GCA Consortium; European Scleroderma Group, Witte T, Neumann T, Holle J, Beretta L, Boiardi L, Emmi G, Cimmino MA, Vaglio A, Herrick AL, Denton CP, Salvarani C, Cid MC, Morgan AW, Fonseca C, González-Gay MA, Martín J, Márquez A.

PLoS One. 2018 Dec 26;13(12):e0209343. doi: 10.1371/journal.pone.0209343. eCollection 2018.

18.

Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan.

19.

Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis.

Bruni C, Ngcozana T, Braschi F, Pucci T, Piemonte G, Benelli L, Poli M, Suliman YA, Guiducci S, Bellando-Randone S, Balduzzi S, Grotts J, Denton CP, Rasero L, Montecucco C, Furst DE, Matucci-Cerinic M.

J Rheumatol. 2019 Jun;46(6):603-608. doi: 10.3899/jrheum.171486. Epub 2018 Nov 15.

PMID:
30442833
20.

Author Correction: Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Nov;14(11):682. doi: 10.1038/s41584-018-0108-3.

PMID:
30317249
21.

European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.

Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, Matucci-Cerinic M, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F.

Rheumatology (Oxford). 2019 Feb 1;58(2):254-259. doi: 10.1093/rheumatology/key271.

PMID:
30239834
22.

Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-ß.

Chaigne B, Clary G, Le Gall M, Dumoitier N, Fernandez C, Lofek S, Chafey P, Moinzadeh P, Krieg T, Denton CP, Mouthon L.

Proteomics Clin Appl. 2019 Jul;13(4):e1800069. doi: 10.1002/prca.201800069. Epub 2018 Sep 6.

PMID:
30141531
23.

Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Sep;14(9):511-527. doi: 10.1038/s41584-018-0062-0. Review. Erratum in: Nat Rev Rheumatol. 2018 Nov;14(11):682.

PMID:
30111804
24.

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2019 Apr 1;58(4):567-579. doi: 10.1093/rheumatology/key151.

25.

Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design.

Hughes M, Tracey A, Bhushan M, Chakravarty K, Denton CP, Dubey S, Guiducci S, Muir L, Ong V, Parker L, Pauling JD, Prabu A, Rogers C, Roberts C, Herrick AL.

J Scleroderma Relat Disord. 2018 Jun 1;3(2):170-174. doi: 10.1177/2397198318764796. Epub 2018 Mar 27.

26.

Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?

Hughes M, Murray A, Denton CP, Herrick AL.

Med Hypotheses. 2018 Jul;116:101-104. doi: 10.1016/j.mehy.2018.04.024. Epub 2018 May 2.

PMID:
29857890
27.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.

28.

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.

Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, Czirják L, Allanore Y, Siegert E, Rosato E, Matucci-Cerinic M, Caimmi C, Henes J, Carreira PE, Smith V, Del Galdo F, Denton CP, Ullman S, De Langhe E, Riccieri V, Alegre-Sancho JJ, Rednic S, Müller-Ladner U, Walker UA; EUSTAR coauthors.

Arthritis Rheumatol. 2018 Nov;70(11):1829-1834. doi: 10.1002/art.40557. Epub 2018 Sep 24.

29.

Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1634-1643. doi: 10.1002/art.40547. Epub 2017 Nov 6.

PMID:
29732731
30.

Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.

Bageghni SA, Hemmings KE, Zava N, Denton CP, Porter KE, Ainscough JFX, Drinkhill MJ, Turner NA.

FASEB J. 2018 Sep;32(9):4941-4954. doi: 10.1096/fj.201701455RR. Epub 2018 Mar 30.

31.

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.

Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E.

Eur Respir J. 2018 Apr 4;51(4). pii: 1701197. doi: 10.1183/13993003.01197-2017. Print 2018 Apr.

PMID:
29563168
32.

The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.

Dhaliwal K, Griffin M, Denton CP, Butler PEM.

BMJ Case Rep. 2018 Mar 9;2018. pii: bcr-2017-219348. doi: 10.1136/bcr-2017-219348.

PMID:
29525756
33.

Reply.

Denton CP, Herrick AL.

Arthritis Rheumatol. 2018 Jun;70(6):974. doi: 10.1002/art.40480. Epub 2018 May 2. No abstract available.

34.

Autologous fat transfer in the successful treatment of upper limb linear morphoea.

Mura S, Fin A, Parodi PC, Denton CP, Howell KJ, Rampino Cordaro E.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):183. Epub 2018 Feb 14. No abstract available.

35.

Development of systemic sclerosis in transgender females: a case series and review of the literature.

Campochiaro C, Host LV, Ong VH, Denton CP.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):50-52. Epub 2018 Feb 19. Review.

36.

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.

Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, Britton J, Buch MH, Del Galdo F, Denton CP, Dinsdale G, Griffiths B, Hall F, Howell K, MacDonald A, McHugh NJ, Manning JB, Pauling JD, Roberts C, Shipley JA, Herrick AL, Murray AK.

Arthritis Rheumatol. 2018 Jun;70(6):903-911. doi: 10.1002/art.40457. Epub 2018 Apr 23.

37.

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Davies S, de Oliveira Pena J, Khanna D.

Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.

38.

Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2.

Gillespie J, Ross RL, Corinaldesi C, Esteves F, Derrett-Smith E, McDermott MF, Doody GM, Denton CP, Emery P, Del Galdo F.

Arthritis Rheumatol. 2018 Jun;70(6):932-942. doi: 10.1002/art.40437. Epub 2018 Apr 23.

39.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G; EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

40.

Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk.

Moreno-Moral A, Bagnati M, Koturan S, Ko JH, Fonseca C, Harmston N, Game L, Martin J, Ong V, Abraham DJ, Denton CP, Behmoaras J, Petretto E.

Ann Rheum Dis. 2018 Apr;77(4):596-601. doi: 10.1136/annrheumdis-2017-212454. Epub 2018 Jan 17.

41.

Molecular Basis for Dysregulated Activation of NKX2-5 in the Vascular Remodeling of Systemic Sclerosis.

Dritsoula A, Papaioannou I, Guerra SG, Fonseca C, Martin J, Herrick AL, Abraham DJ, Denton CP, Ponticos M.

Arthritis Rheumatol. 2018 Jun;70(6):920-931. doi: 10.1002/art.40419. Epub 2018 Apr 24.

42.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2018 Apr;77(4):563-570. doi: 10.1136/annrheumdis-2017-211912. Epub 2018 Jan 6.

43.

Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor.

Liakouli V, Elies J, El-Sherbiny YM, Scarcia M, Grant G, Abignano G, Derrett-Smith EC, Esteves F, Cipriani P, Emery P, Denton CP, Giacomelli R, Mavria G, Del Galdo F.

Ann Rheum Dis. 2018 Mar;77(3):431-440. doi: 10.1136/annrheumdis-2017-212120. Epub 2017 Dec 19.

44.

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.

Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL.

Rheumatology (Oxford). 2018 Feb 1;57(2):370-381. doi: 10.1093/rheumatology/kex410.

45.

Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis.

Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, Mageed RA.

Arthritis Rheumatol. 2018 Mar;70(3):450-461. doi: 10.1002/art.40390. Epub 2018 Feb 6.

46.

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.

Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators.

Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242.

47.

The Fine Line between Success and Failure in Scleroderma Lung Fibrosis Trials.

Ryerson CJ, Denton CP.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):553-554. doi: 10.1164/rccm.201711-2268ED. No abstract available.

PMID:
29186664
48.

Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis.

Allanore Y, Distler O, Matucci-Cerinic M, Denton CP.

Arthritis Rheumatol. 2018 Feb;70(2):162-170. doi: 10.1002/art.40377. Epub 2018 Jan 22. Review.

49.

STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation.

Papaioannou I, Xu S, Denton CP, Abraham DJ, Ponticos M.

Mol Biol Cell. 2018 Jan 15;29(2):84-95. doi: 10.1091/mbc.E17-06-0342. Epub 2017 Nov 15.

50.

Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.

Pope JE, Lee JJ, Denton CP.

Arthritis Rheumatol. 2018 Feb;70(2):155-156. doi: 10.1002/art.40373. Epub 2017 Dec 29. No abstract available.

Supplemental Content

Loading ...
Support Center